ALNY · NASDAQ
Alnylam Pharmaceuticals (ALNY) Stock Price & Fundamentals
Alnylam Pharmaceuticals (ALNY) closed at $305.93 on Oct 9, 2026, down 0.49% from the previous close of $307.45.
Share price, past year
1Y +31.17%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $305.93 |
| Sep 30, 2026 | $310.08 |
| Aug 31, 2026 | $313.84 |
| Jul 31, 2026 | $303.05 |
| Jun 30, 2026 | $320.55 |
| May 29, 2026 | $314.27 |
| Apr 30, 2026 | $291.78 |
| Mar 31, 2026 | $265.90 |
| Feb 27, 2026 | $253.49 |
| Jan 30, 2026 | $243.20 |
| Dec 31, 2025 | $236.76 |
| Nov 28, 2025 | $237.31 |
| Oct 31, 2025 | $239.67 |
Key statistics
- Market cap
- $40.91B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- $774.71M
- Shares outstanding
- 133.7M
- Dividend yield
- —
- 52-week range
- $232.71 – $327.08
Alnylam Pharmaceuticals's market cap is $40.91B, based on a share price of $305.93 and 133.7M shares outstanding as of Jun 30, 2026.
Financials
Alnylam Pharmaceuticals reported revenue of $3.71B for fiscal 2025, up 65.19% from fiscal 2024.
Alnylam Pharmaceuticals earned net income of $313.75M in fiscal 2025, a net margin of 8.4%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $3.71B | +65.2% | $313.75M | 8.5% | $2.33 | $465.38M |
| FY2024ended Dec 31, 2024 | $2.25B | +23.0% | −$278.16M | −12.4% | −$2.18 | −$42.59M |
| FY2023ended Dec 31, 2023 | $1.83B | +76.2% | −$440.24M | −24.1% | −$3.52 | $41.95M |
| FY2022ended Dec 31, 2022 | $1.04B | +22.9% | −$1.13B | −109.0% | −$9.30 | −$613.33M |
| FY2021ended Dec 31, 2021 | $844.29M | +71.3% | −$852.82M | −101.0% | −$7.20 | −$718.07M |
| FY2020ended Dec 31, 2020 | $492.85M | +124.3% | −$858.28M | −174.2% | −$7.46 | −$685.32M |
| FY2019ended Dec 31, 2019 | $219.75M | +193.4% | −$886.12M | −403.2% | −$8.11 | −$418.58M |
| FY2018ended Dec 31, 2018 | $74.91M | −16.7% | −$761.50M | −1,016.6% | −$7.57 | −$689.50M |
| FY2017ended Dec 31, 2017 | $89.91M | +90.7% | −$490.87M | −546.0% | −$5.42 | −$487.00M |
| FY2016ended Dec 31, 2016 | $47.16M | — | −$410.11M | −869.6% | −$4.79 | −$372.26M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.29B | $164.49M | $1.21 |
| Q4 FY2025ended Dec 31, 2025 | $1.10B | $153.14M | $1.18 |
| Q3 FY2025ended Sep 30, 2025 | $1.25B | $251.08M | $1.84 |
| Q2 FY2025ended Jun 30, 2025 | $773.69M | −$72.23M | −$0.55 |
| Q1 FY2025ended Mar 31, 2025 | $594.19M | −$18.25M | −$0.14 |
| Q4 FY2024ended Dec 31, 2024 | $593.17M | −$83.76M | −$0.66 |
| Q3 FY2024ended Sep 30, 2024 | $500.92M | −$111.57M | −$0.87 |
| Q2 FY2024ended Jun 30, 2024 | $659.83M | — | −$0.13 |
Company profile
- Name
- Alnylam Pharmaceuticals, Inc.
- Ticker
- ALNY
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142
- Fiscal year ends
- December
- SEC CIK
- 0001178670
Recent SEC filings
- Jul 30, 2026
- Jul 30, 2026
- May 27, 2026
- Apr 30, 2026
- Apr 30, 2026
- Mar 4, 2026
- Feb 12, 2026
- Feb 12, 2026
Frequently asked questions
What is Alnylam Pharmaceuticals's stock price?
Alnylam Pharmaceuticals (ALNY) closed at $305.93 on Oct 9, 2026, down 0.49% from the previous close of $307.45.
What is Alnylam Pharmaceuticals's market cap?
Alnylam Pharmaceuticals's market cap is $40.91B, based on a share price of $305.93 and 133.7M shares outstanding as of Jun 30, 2026.
How much revenue does Alnylam Pharmaceuticals make?
Alnylam Pharmaceuticals reported revenue of $3.71B for fiscal 2025, up 65.19% from fiscal 2024.
Does Alnylam Pharmaceuticals pay a dividend?
Alnylam Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Alnylam Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures